Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

A recent study has revealed that even when psoriasis patients achieve clear or nearly clear skin through biologic therapies, many continue to experience systemic inflammation, ...

Moore spent over two decades going to the doctor with her endometriosis symptoms in a “relentless fight to be heard” before receiving a diagnosis, but said she was diagnosed with psoriasis ...

including lipids, metabolites, and peptides; clinical markers ... to assist with PsA diagnosis (iPROLEPSIS), to distinguish subtypes of atopic dermatitis and psoriasis using biomarkers (BIOMAP ...

A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic dermatitis and psoriasis molecular markers. Image: Adobe Stock.

Despite well-established clinical manifestations, the differential diagnosis between inflammatory linear verrucous epidermal nevus and linear psoriasis remains difficult ... Involucrin is a marker of ...

and cardiovascular risk markers. Eligible participants were 18 years or older and had a diagnosis of moderate to severe plaque psoriasis. A total of 20 patients were included; 55% were male ...

These results suggest that the presence of eosinophils does not contradict a psoriasis diagnosis, and furthermore, that their quantity may correlate with specific histopathological features. This ...